3篇
您的检索式：作者名="Elad Sharon"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | IGF-1R as an anti-cancer target—trials and tribulations显示文摘Type I insulin-like growth factor receptor (IGF-1R) has long been recognized for its role in tumorigenesis and growth, but only recently have the tools for targeting the IGF pathway become available. More than 10 IGF/IGF-1R inhibitors have entered clinical trials, and these belong to three main classes: (1) monoclonal antibodies against IGF-1R, (2) monoclonal antibodies against IGF-1R ligands (IGF-1 and IGF- 2), and (3) IGF-1R tyrosine kinase inhibitors. These IGF-1R-targeting agents share common effects on IGF-1R signaling but differ in mechanisms of action, spectrum of target inhibition, and pharmacological features. Clinical activity of IGF-1R inhibitors has been demonstrated with sustained responses in a small number of patients with select tumor types, such as Ewing sarcoma and thymoma. However, many large clinical trials involving patients with adult tumors, including non-small cell lung cancer, breast cancer, and pancreatic cancer, failed to show clinical benefit in the overall patient population. Possible reasons for failure include the complexity of the IGF-1R/insulin receptor system and parallel growth and survival pathways, as well as a lack of patient selection markers. While IGF-1R remains a valid target for selected tumor types, identification of predictive markers and rational combinations will be critical to success in future development. | Helen X. Chen Elad Sharon | 2013 | Chinese Journal of Cancer2013，32，5： | 16 |
| 2 | Immune checkpoint inhibitors in clinical trials显示文摘Immunology-based therapy is rapidly developing into an effective treatment option for a surprising range of cancers. We have learned over the last decade that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by specific molecules often called 'immune checkpoints.' These checkpoints serve to control or turn off the immune response when it is no longer needed to prevent tissue injury and autoimmunity. Cancer cells have learned or evolved to use these mechanisms to evade immune control and elimination. The development of a new therapeutic class of drugs that inhibit these inhibitory pathways has recently emerged as a potent strategy in oncology. Three sets of agents have emerged in clinical trials exploiting this strategy. These agents are antibodybased therapies targeting cytotoxic T-lymphocyte antigen 4(CTLA4), programmed cell death 1(PD-1), and programmed cell death ligand 1(PD-L1). These inhibitors of immune inhibition have demonstrated extensive activity as single agents and in combinations. Clinical responses have been seen in melanoma, renal cell carcinoma, non-small cell lung cancer, and several other tumor types. Despite the autoimmune or inflammatory immune-mediated adverse effects which have been seen, the responses and overall survival benefits exhibited thus far warrant further clinical development. | Elad Sharon Howard Streicher Priscila Goncalves Helen X.Chen | 2014 | Chinese Journal of Cancer2014，33，9： | 14 |
| 3 | Systematic review of agents for the management of gastrointestinal mucositis in cancer patients显示文摘 | Rachel J. Gibson Dorothy M. K. Keefe Rajesh V. Lalla Emma Bateman Nicole Blijlevens Margot Fijlstra Emily E. King Andrea M. Stringer Walter J. F. M. Velden Roger Yazbeck Sharon Elad Joanne M. Bowen | 2013 | Supportive Care in Cancer2013，，1： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员